In a successful bid to introduce its groundbreaking 3D cell culturing technology to a budding generation of “MAD” scientists, Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D BioSciences (n3D) has announced the winners of an intriguing scientific discovery competition, The MAD Scientist Contest by n3D. The top cash prize was awarded to Hamsa Jaganathan, Ph.D., of the Methodist Hospital Research Institute for her amazing model of a breast tumor microenvironment, created by co-culturing breast cancer cells and fibroblasts. Second prize went to Matthew Hogan at the University of Houston for his creation of a functional, or beating, primary cardiac cultures in vitro. “The winning entries illustrate how 3-D, suspended cultures constructed using n3D technology improve data and achieve results impossible with other cell-culturing systems,” said RBCC CEO Patrick Brown. “The MAD Scientist Contest also served to introduce n3D's Bio-Assembler system to the young scientists who will undoubtedly lead cellular research into the future.” This contest is a critical piece of n3D and RBCC's strategy to build strong interest in the Bio-Assembler among researchers across a broad spectrum of scientific and research disciplines. The system's revolutionary functionality allows it to produce accurate, 3D representations of in vivo tissues faster and easier than any other existing technology. RBCC formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). Rainbow BioSciences acquired an equity interest in n3D earlier last year. For more information on RBCC’s other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html. About Rainbow BioSciences Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC).The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html. Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.